Lindsay Fischer


Ribociclib Dose Reductions Do Not Affect Survival Outcomes in HR+/HER2- Advanced Breast Cancer

June 7th 2022

Overall survival outcomes for patients with hormone receptor–positive, HER2-negative advanced breast cancer who had dose modifications of ribociclib in the phase 3 MONALEESA-2 trial were comparable to those seen among patients who received the standard dose.

Avasopasem Reduces Severe Oral Mucositis In Patients Receiving Chemoradiotherapy for Advanced Head and Neck Cancer

June 4th 2022

Avasopasem significantly reduced severe oral mucositis across all intensity-modulated radiotherapy landmarks in patients with locally advanced, nonmetastatic head and neck cancer.

Co-Treatment With Vitamin C Increases Therapeutic Effect of Chemotherapy in Cisplatin-Ineligible MIBC

May 15th 2022

Cisplatin-ineligible patients with locally advanced muscle invasive bladder cancer undergoing chemotherapy may benefit from simultaneous treatment with intravenous vitamin C.

Immune-Related Adverse Effects Linked to Longer Survival With Pembrolizumab in Metastatic Urothelial Carcinoma

May 13th 2022

Patients with metastatic urothelial carcinoma who received pembrolizumab achieved prolonged median progression-free and overall survival after experiencing an immune-related adverse effect.

Belimumab Emerges as Potential Prophylaxis for Chronic GVHD Following Allogenic Transplant

April 24th 2022

Belimumab could be a potential treatment used to prevent chronic graft-vs-host-disease in patients undergoing allogeneic hematopoietic transplantation by inhibiting BAFF and limiting the survival of aforeactive B cells.

TTX-030 Plus Budigalimab/mFOLFOX6 Induces Responses in PD-L1–Low Advanced Gastric/GEJ Cancer

April 12th 2022

The addition of the investigational anti-CD39 antibody TTX-030 to frontline treatment with the PD-L1 inhibitor budigalimab and mFOLFOX6 was determined to be safe and tolerable in patients with locally advanced or metastatic HER2-negative gastroesophageal junction adenocarcinoma.

YAP1, Inflamed T-Cell Subtypes Linked With Improved Durvalumab/ Chemo Responses in ES-SCLC

April 11th 2022

Patients with extensive-stage small cell lung cancer whose disease harbors inflamed or YAP1 molecular subtypes may be more likely to derive superior overall survival benefit from durvalumab and chemotherapy vs those with other overexpressed biomarkers.

Phase 3 Trial Seeks to Confirm Oregovomab Benefit in Advanced Ovarian Cancer

March 18th 2022

Oregovomab, an investigational monoclonal antibody with promising phase 2 data, is being tested in combination with paclitaxel for patients with advanced epithelial ovarian cancer in the phase 3 FLORA-5 trial.

Nivolumab/Ipilimumab Shows Superior QOL in Advanced RCC

February 24th 2022

The combination of nivolumab and ipilimumab led to superior quality of life compared with sunitinib in the frontline setting of patients with advanced renal cell carcinoma, according to results of a 5-year analysis from the CheckMate 214 trial.

Pembrolizumab/Chemo Combo Emerges as Standard of Care in Esophageal Cancer/GEJ Adenocarcinoma

January 21st 2022

Updated findings from the KEYNOTE-590 study confirmed the clinical benefit of the combination of pembrolizumab and chemotherapy as a treatment for patients with locally advanced and metastatic esophageal cancer.

Key Markers in Gut Microbiome May Predict Skin-Related AEs With Nivolumab in Advanced Gastric Cancer

January 20th 2022

The presence of Arthrobacter and fatty acid metabolism pathways in gut microbiomes may be linked to an increased risk of skin-related adverse events in patients with advanced gastric cancer who are receiving single-agent nivolumab.

Belantamab Mafodotin/Pd Triplet Demonstrates Manageable Safety Profile in Relapsed/Refractory Myeloma

December 17th 2021

The triplet regimen of belantamab mafodotin plus pomalidomide and dexamethasone was revealed to have a manageable safety profile, which is consistent with the known individual safety profiles of belantamab mafodotin or pomalidomide and dexamethasone, in patients with relapsed/refractory multiple myeloma.

Amphiregulin Represents Potentially Predictive Biomarker in Acute GVHD

December 15th 2021

Elevated amphiregulin was associated with increased mortality risk in acute graft–versus-host-disease, according to a sample of 2 prospective clinical trials showed.

Link Between Elevated WBC and Thrombotic Events in Polycythemia Vera Highlights Potential Prevention Strategy

December 14th 2021

Patients with polycythemia vera who have controlled hematocrit levels, but elevated white blood counts are at an increased risk of thrombotic events, according to a presentation of the REVEAL study.

Venetoclax/Selinexor Combo Shows Efficacy in Relapsed/Refractory Multiple Myeloma With t(11;14)

December 13th 2021

Selinexor combined with venetoclax demonstrated efficacy and tolerability in heavily pretreated relapsed/refractory multiple myeloma cell lines with t(11;14), according to small study results that were presented during the 2021 ASH Annual Meeting.

Pirtobrutinib Overcomes Ibrutinib, Venetoclax Resistance in Heavily Pretreated MCL Cell Lines

December 12th 2021

The novel non-covalent BTK inhibitor pirtobrutinib showed promising preclinical efficacy in overcoming ibrutinib and venetoclax resistance, and in limiting cell growth and inducing apoptosis in mantle cell lymphoma.

Aromatase Inhibitors Significantly Reduce Recurrence in Premenopausal ER+ Breast Cancer

December 8th 2021

Aromatase inhibitors significantly reduced the risk of breast cancer recurrence in premenopausal women with estrogen receptor–positive breast cancer receiving ovarian suppression compared with tamoxifen.

Examining the Role of the Nurse Coordinator in the CheckMate-73L Trial of Nivolumab/Ipilimumab in NSCLC

September 28th 2021

Sandra Duncan, RN, BSN, shares her experience with the CheckMate-73L trial of ipilimumab/nivolumab in non–small cell lung cancer, efforts made to overcome communication challenges, and the importance of nurse coordinators in the realm of clinical trials.

Darolutamide Plus ADT Demonstrates Similar Safety Profile Vs ADT Alone in Nonmetastatic CRPC

September 16th 2021

The safety profile of daralutamide in combination with androgen-deprivation therapy was similar to placebo in patients with nonmetastatic castration-resistant prostate cancer.

Novel Neoadjuvant Triplet Shows Preliminary Promise in Resectable Pleural Mesothelioma

September 13th 2021

Neoadjuvant treatment with cisplatin/pemetrexed plus atezolizumab, followed by maintenance atezolizumab, demonstrated early efficacy with acceptable safety in patients with resectable pleural mesothelioma.